Preclinical Studies of Weizmannia (Bacillus) coagulans BC99

As of February 2026,approximately 14 animal studies have been conducted on BC99.Utilizing various animal models,

these studies have provided in-depth insights into the effects and mechanisms of BC99 on intestinal microbiota,intestinal   barrier  function,intestinal  metabolism,intestinal   immunity,

and intestinal motility.

Multiple clinical studies have extensively investigated the efficacy of BC99 in human subjects,yielding critical human data that

provide robust support for the application potential of BC99.

To achieve a more comprehensive and in-depth understanding of its functional properties,systematic investigations of BC99 have  been conducted using various animal models.

Animal experiments have not only validated the core functions of the strain under controlled conditions but have also enriched the  evidence base for its functionality from multiple additional

dimensions.These preclinical findings corroborate the results from clinical studies and provide valuable references for

subsequent research into the underlying mechanisms of action.